Terms: = Ovarian cancer AND MDM2, HDM2, 4193, ENSG00000135679, HDMX, MGC71221, hdm2, Q00987 AND Prognosis
25 results:
1. Identification of mdm2 as a prognostic and immunotherapeutic biomarker in a comprehensive pan-cancer analysis: A promising target for breast cancer, bladder cancer and ovarian cancer immunotherapy.
Zheng J; Miao F; Wang Z; Ma Y; Lin Z; Chen Y; Kong X; Wang Y; Zhuang A; Wu T; Li W
Life Sci; 2023 Aug; 327():121832. PubMed ID: 37276911
[TBL] [Abstract] [Full Text] [Related]
2. Enhancement of mdm2 inhibitory effects through blocking nuclear export mechanisms in ovarian cancer cells.
Alzahrani A; Natarajan U; Rathinavelu A
Cancer Genet; 2022 Aug; 266-267():57-68. PubMed ID: 35785714
[TBL] [Abstract] [Full Text] [Related]
3. Gain-of-Function Mutant TP53 R248Q Overexpressed in Epithelial ovarian Carcinoma Alters AKT-Dependent Regulation of Intercellular Trafficking in Responses to EGFR/mdm2 Inhibitor.
Lai ZY; Tsai KY; Chang SJ; Chuang YJ
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445495
[TBL] [Abstract] [Full Text] [Related]
4. Larotrectinib in a Patient With Advanced Pleomorphic Liposarcoma of the Uterus.
Valenciaga A; Iwenofu OH; Tinoco G
J Natl Compr Canc Netw; 2021 Jul; 19(7):775-779. PubMed ID: 34340207
[TBL] [Abstract] [Full Text] [Related]
5. Circular RNA S-7 promotes ovarian cancer EMT via sponging miR-641 to up-regulate ZEB1 and mdm2.
Zhang F; Xu Y; Ye W; Jiang J; Wu C
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32667627
[TBL] [Abstract] [Full Text] [Related]
6. Tumor suppressor OTUD3 induces growth inhibition and apoptosis by directly deubiquitinating and stabilizing p53 in invasive breast carcinoma cells.
Pu Q; Lv YR; Dong K; Geng WW; Gao HD
BMC Cancer; 2020 Jun; 20(1):583. PubMed ID: 32571254
[TBL] [Abstract] [Full Text] [Related]
7. Genomic and Molecular Abnormalities in Gynecologic Clear Cell Carcinoma.
Marks EI; Brown VS; Dizon DS
Am J Clin Oncol; 2020 Feb; 43(2):139-145. PubMed ID: 31764020
[TBL] [Abstract] [Full Text] [Related]
8. Upregulation of circular RNA circ‑FAM53B predicts adverse prognosis and accelerates the progression of ovarian cancer via the miR‑646/VAMP2 and miR‑647/mdm2 signaling pathways.
Sun D; Liu J; Zhou L
Oncol Rep; 2019 Dec; 42(6):2728-2737. PubMed ID: 31638250
[TBL] [Abstract] [Full Text] [Related]
9. SMYD3 promotes epithelial ovarian cancer metastasis by downregulating p53 protein stability and promoting p53 ubiquitination.
Zhang L; Jin Y; Yang H; Li Y; Wang C; Shi Y; Wang Y
Carcinogenesis; 2019 Dec; 40(12):1492-1503. PubMed ID: 31002112
[TBL] [Abstract] [Full Text] [Related]
10. The USP7 Inhibitor P5091 Induces Cell Death in ovarian cancers with Different P53 Status.
Wang M; Zhang Y; Wang T; Zhang J; Zhou Z; Sun Y; Wang S; Shi Y; Luan X; Zhang Y; Wang Y; Wang Y; Zou Z; Kang L; Liu H
Cell Physiol Biochem; 2017; 43(5):1755-1766. PubMed ID: 29049989
[TBL] [Abstract] [Full Text] [Related]
11. mdm2 promotes epithelial-mesenchymal transition and metastasis of ovarian cancer SKOV3 cells.
Chen Y; Wang DD; Wu YP; Su D; Zhou TY; Gai RH; Fu YY; Zheng L; He QJ; Zhu H; Yang B
Br J Cancer; 2017 Oct; 117(8):1192-1201. PubMed ID: 28817834
[TBL] [Abstract] [Full Text] [Related]
12. Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative.
Edmondson RJ; Crosbie EJ; Nickkho-Amiry M; Kaufmann A; Stelloo E; Nijman HW; Leary A; Auguste A; Mileshkin L; Pollock P; MacKay HJ; Powell ME; Bosse T; Creutzberg CL; Kitchener HC
Gynecol Oncol; 2017 Aug; 146(2):327-333. PubMed ID: 28511869
[TBL] [Abstract] [Full Text] [Related]
13. mdm2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53.
Makii C; Oda K; Ikeda Y; Sone K; Hasegawa K; Uehara Y; Nishijima A; Asada K; Koso T; Fukuda T; Inaba K; Oki S; Machino H; Kojima M; Kashiyama T; Mori-Uchino M; Arimoto T; Wada-Hiraike O; Kawana K; Yano T; Fujiwara K; Aburatani H; Osuga Y; Fujii T
Oncotarget; 2016 Nov; 7(46):75328-75338. PubMed ID: 27659536
[TBL] [Abstract] [Full Text] [Related]
14. Clinical and Emergent Biomarkers and Their Relationship to the prognosis of ovarian cancer.
Jatoi A; Vierkant RA; Hawthorne KM; Block MS; Ramus SJ; Larson NB; Fridley BL; Goode EL
Oncology; 2016; 90(2):59-68. PubMed ID: 26780780
[TBL] [Abstract] [Full Text] [Related]
15. mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
[TBL] [Abstract] [Full Text] [Related]
16. mdm2 SNP309 modifies the prognostic significance of the p53 mutational status in patients with ovarian cancer.
Hofstetter G; Berger A; Bauer EM; Schuster E; Wolf A; Chamson M; Müller-Holzner E; Reimer D; Braicu EI; Sehouli J; Ulmer H; Cacsire Castillo-Tong D; Zeillinger R; Concin N
Oncol Rep; 2012 Mar; 27(3):673-7. PubMed ID: 22134502
[TBL] [Abstract] [Full Text] [Related]
17. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.
Ahmed AA; Etemadmoghadam D; Temple J; Lynch AG; Riad M; Sharma R; Stewart C; Fereday S; Caldas C; Defazio A; Bowtell D; Brenton JD
J Pathol; 2010 May; 221(1):49-56. PubMed ID: 20229506
[TBL] [Abstract] [Full Text] [Related]
18. Alteration of cell cycle regulators correlates with survival in epithelial ovarian cancer patients.
Hashiguchi Y; Tsuda H; Inoue T; Nishimura S; Suzuki T; Kawamura N
Hum Pathol; 2004 Feb; 35(2):165-75. PubMed ID: 14991533
[TBL] [Abstract] [Full Text] [Related]
19. Independence of the prognostic value of tumor suppressor protein expression in ovarian adenocarcinomas: A multivariate analysis of expression of p53, retinoblastoma, and related proteins.
Tachibana M; Watanabe J; Matsushima Y; Nishida K; Kobayashi Y; Fujimura M; Shiromizu K
Int J Gynecol Cancer; 2003; 13(5):598-606. PubMed ID: 14675342
[TBL] [Abstract] [Full Text] [Related]
20. Prognostic significance of the infiltrative pattern invasion in endometrioid adenocarcinoma of the endometrium.
Suzuki C; Matsumoto T; Sonoue H; Arakawa A; Furugen Y; Kinoshita K
Pathol Int; 2003 Aug; 53(8):495-500. PubMed ID: 12895227
[TBL] [Abstract] [Full Text] [Related]
[Next]
